Xiaoqing Mu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Xiaoqing Mu has a total of 42 co-authors. Here are the top co-authors by number of shared publications:
Yan Xu
10 shared publications- Yao Nie
Jiangnan University
10 shared publications Tao Wu
7 shared publications- Yan Xu
Key Laboratory of Industrial Biotechnology of Ministry of Education, School of Biotechnology, Jiangnan University, Wuxi 214122, China
5 shared publications - Tao Wu
Huaiyin Normal University
3 shared publications Yao Nie
Laboratory of Brewing Microbiology and Applied Enzymology School of Biotechnology Jiangnan University 214122 Wuxi P. R. China
3 shared publications
Latest Publications
- 11 September 2026
- Published by American Chemical Society (ACS) in ACS Sustainable Chemistry & Engineering
- Vol. 14 (38) , 17174-17184
Engineering an F-Amine Dehydrogenase for Efficient and Sustainable Biocatalytic Synthesis of a Chiral PDE10 Inhibitor Precursor
(R)–4-(1H-indol-3-yl)butan-2-amine ((R)-4IBA), encompassing a nitrogen heterocycle and a chiral primary amino group, is a highly appealing precursor in the pharmaceutical domain. The direct amination of the readily available prochiral ketone 4-(1H-indol-3-yl)butan-2-one (4IBO) catalyzed by amine dehydrogenases (AmDHs) represents a green and sustainable synthetic route for (R)-4IBA, as it consumes only ammonia and releases water as the sole byproduct. However, AmDH-based biocatalytic synthesis of (R)-4IBA remains challenging due to the absence of available AmDH biocatalysts. Here, we engineered the phenylalanine AmDH originating from Bacillus badius (F-BbAmDH) for the biocatalytic synthesis of (R)-4IBA. By combining combinatorial active-site saturation test (CAST) and focused rational iterative site-specific mutagenesis (FRISM) strategies, a quintuple mutant M3-1 (V144G/L306V/V309G/Q308A/T124A) was identified with a 56.6-fold increased kcat/Km value toward substrate 4IBO. The practical application potential of M3-1 was verified in a preparative-scale biosynthesis of (R)-4IBA with a substrate fed-batch strategy. A total of 109.6 mM 4IBO was effectively transformed with 91.7% conversion after four times fed-batch operations, and the product (R)-4IBA was prepared in 82.4% isolated yield and up to 99% ee. Our work presents the first instance of the preparation of (R)-4IBA through enzyme-based sustainable biosynthesis.
- 11 September 2026
- Published by American Chemical Society (ACS) in ACS Sustainable Chemistry & Engineering
- Vol. 14 (38) , 17174-17184
Engineering an F-Amine Dehydrogenase for Efficient and Sustainable Biocatalytic Synthesis of a Chiral PDE10 Inhibitor Precursor
(R)–4-(1H-indol-3-yl)butan-2-amine ((R)-4IBA), encompassing a nitrogen heterocycle and a chiral primary amino group, is a highly appealing precursor in the pharmaceutical domain. The direct amination of the readily available prochiral ketone 4-(1H-indol-3-yl)butan-2-one (4IBO) catalyzed by amine dehydrogenases (AmDHs) represents a green and sustainable synthetic route for (R)-4IBA, as it consumes only ammonia and releases water as the sole byproduct. However, AmDH-based biocatalytic synthesis of (R)-4IBA remains challenging due to the absence of available AmDH biocatalysts. Here, we engineered the phenylalanine AmDH originating from Bacillus badius (F-BbAmDH) for the biocatalytic synthesis of (R)-4IBA. By combining combinatorial active-site saturation test (CAST) and focused rational iterative site-specific mutagenesis (FRISM) strategies, a quintuple mutant M3-1 (V144G/L306V/V309G/Q308A/T124A) was identified with a 56.6-fold increased kcat/Km value toward substrate 4IBO. The practical application potential of M3-1 was verified in a preparative-scale biosynthesis of (R)-4IBA with a substrate fed-batch strategy. A total of 109.6 mM 4IBO was effectively transformed with 91.7% conversion after four times fed-batch operations, and the product (R)-4IBA was prepared in 82.4% isolated yield and up to 99% ee. Our work presents the first instance of the preparation of (R)-4IBA through enzyme-based sustainable biosynthesis.
- 24 February 2025
- Published by American Chemical Society (ACS) in ACS Food Science & Technology
- Vol. 5 (3) , 1193-1207
Multiomics Insights into Microbiome Succession throughout Medium-Temperature Daqu Fermentation
- 24 February 2025
- Published by American Chemical Society (ACS) in ACS Food Science & Technology
- Vol. 5 (3) , 1193-1207
Multiomics Insights into Microbiome Succession throughout Medium-Temperature Daqu Fermentation
- 30 December 2024
- Published by American Chemical Society (ACS) in ACS Catalysis
- Vol. 15 (2) , 877-888
Unlocking the Substrate Acceptance of Phenylalanine Amine Dehydrogenase Enables the Asymmetric Synthesis of Pharmaceutical N-Heterocyclic Primary Amines
- 30 December 2024
- Published by American Chemical Society (ACS) in ACS Catalysis
- Vol. 15 (2) , 877-888
Unlocking the Substrate Acceptance of Phenylalanine Amine Dehydrogenase Enables the Asymmetric Synthesis of Pharmaceutical N-Heterocyclic Primary Amines
- 19 April 2024
- Published by American Chemical Society (ACS) in ACS Food Science & Technology
- Vol. 4 (5) , 1255-1264
Directional Mining and Thermostability Modification of Novel Acid-Resistant Maltogenic Amylase from Lactobacillus paralimentarius
- 19 April 2024
- Published by American Chemical Society (ACS) in ACS Food Science & Technology
- Vol. 4 (5) , 1255-1264
Directional Mining and Thermostability Modification of Novel Acid-Resistant Maltogenic Amylase from Lactobacillus paralimentarius
- 7 February 2024
- Published by American Chemical Society (ACS) in ACS Catalysis
- Vol. 14 (4) , 2685-2695
Shield Machine-like Substrate Walking Strategy-Based Pocket Engineering of F-Amine Dehydrogenase for Accessing Structurally Diverse Fused-Ring and Linked-Ring Aryl Ketones
- 7 February 2024
- Published by American Chemical Society (ACS) in ACS Catalysis
- Vol. 14 (4) , 2685-2695
Shield Machine-like Substrate Walking Strategy-Based Pocket Engineering of F-Amine Dehydrogenase for Accessing Structurally Diverse Fused-Ring and Linked-Ring Aryl Ketones
- Open Access
Comprehensive Transformation of Escherichia coli for Nicotinamide Mononucleotide Production
Nicotinamide mononucleotide (NMN) is a key precursor of nicotinamide adenine dinucleotide and an important source of cellular energy. It can prevent neuronal mitochondrial defects and alleviate heart fibrosis. Strategies to improve NMN production have important implications for human health. Through plasmid expression technology and CRISPR/Cas9 technology, we engineered Escherichia coli for efficient NMN production. First, we upregulated the expression of genes encoding key enzymes in the NMN synthesis pathway, enabling E. coli to directly produce NMN, and established the important role of the nicotinamide mononucleotide transporter in the transport of NMN from cells. The content of NMN was 0.24 g·L−1 at 24 h. Second, we strengthened the adenosine triphosphate (ATP) cycle, and the concentration of NMN was 0.49 g·L−1 at 24 h. Third, we increased the synthesis of the NMN precursor 5-phosphate ribose-1-phosphate and obtained an NMN content of 0.49 g·L−1 at 12 h and 1.11 g·L−1 at 24 h. Fourth, we introduced nicotinamide riboside kinase (NRK) and found that it was effective only for a period of time. The content of NMN was 0.54 g·L−1 at 12 h but only 1.05 g·L−1 at 24 h. Finally, we combined these strategies to regulate the whole metabolic flow, revealing that integrating multiple pathways promoted NMN production. During fermentation, we added 1 g·L−1 nicotinamide and 10 g·L−1 glucose, yielding an extracellular NMN concentration of 1.11 g·L−1.
Open AccessComprehensive Transformation of Escherichia coli for Nicotinamide Mononucleotide Production
Nicotinamide mononucleotide (NMN) is a key precursor of nicotinamide adenine dinucleotide and an important source of cellular energy. It can prevent neuronal mitochondrial defects and alleviate heart fibrosis. Strategies to improve NMN production have important implications for human health. Through plasmid expression technology and CRISPR/Cas9 technology, we engineered Escherichia coli for efficient NMN production. First, we upregulated the expression of genes encoding key enzymes in the NMN synthesis pathway, enabling E. coli to directly produce NMN, and established the important role of the nicotinamide mononucleotide transporter in the transport of NMN from cells. The content of NMN was 0.24 g·L−1 at 24 h. Second, we strengthened the adenosine triphosphate (ATP) cycle, and the concentration of NMN was 0.49 g·L−1 at 24 h. Third, we increased the synthesis of the NMN precursor 5-phosphate ribose-1-phosphate and obtained an NMN content of 0.49 g·L−1 at 12 h and 1.11 g·L−1 at 24 h. Fourth, we introduced nicotinamide riboside kinase (NRK) and found that it was effective only for a period of time. The content of NMN was 0.54 g·L−1 at 12 h but only 1.05 g·L−1 at 24 h. Finally, we combined these strategies to regulate the whole metabolic flow, revealing that integrating multiple pathways promoted NMN production. During fermentation, we added 1 g·L−1 nicotinamide and 10 g·L−1 glucose, yielding an extracellular NMN concentration of 1.11 g·L−1.